MONDAY, SEPTEMBER 26, 2016

Hemispherx receives positive opinion for MERS treatment

Positive feedback for MERS treatment from Hemispherx Biopharma Europe | Courtesy of dohanews.co
Hemispherx Biopharma Europe NV/SA, a branch of Hemispherx Biopharma Inc., recently announced that it has received a positive opinion for its new Middle East Respiratory Syndrome (MERS) treatment from the Committee on Medical Products (COMP).

The positive review is about the company’s Orphan Medical Product Application for its new Alferon N Injection. COMP stated the product meets all criteria specified for designation. The organization also said that the sponsor has sufficiently proved there are not any current treatments for MERS.

In light of this, COMP has issued a recommendation that Alergon N Injection receive orphan medical product designation for MERS indication.

In 2012, health professionals first identified MERS  in Saudi Arabia. This illness is due to the Middle East Respiratory Syndrome Coronavirus. MERS infections result in severe acute respiratory illness and cough, fever, and shortness of breath. Some patients die from the disease, and others develop pneumonia, nausea/vomiting, diarrhea, gastrointestinal symptoms and kidney failure.

"Alferon has great experimental potential as an early onset therapeutic for this dread disease,” Hemispherx President Tom Equels said. “Hemispherx is dedicated to making Alferon available for MERS clinical trials, emergency uses and early access programs consistent with all applicable laws.”

Organizations in this story

Hemispherx Biopharma, Inc. 1617 John F Kennedy Blvd Philadelphia, PA 19103

Get notified the next time we write about Hemispherx Biopharma, Inc.!